STOK

$0.00

(

+0.00%

)
Quote details

stock

Stoke Therapeutics Inc

NASDAQ | STOK

24.14

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$1.26B

Market Cap

26.38

P/E Ratio

0.87

EPS

$24.60

52 Week High

$5.35

52 Week Low

HEALTHCARE

Sector

STOK Chart

Recent Chart
Price Action

STOK Technicals

Tags:

STOK Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $37M
Total Revenue $37M
Cost Of Revenue $4.4M
Costof Goods And Services Sold $4.4M
Operating Income -$101M
Selling General And Administrative $49M
Research And Development $89M
Operating Expenses $138M
Investment Income Net -
Net Interest Income $13M
Interest Income -
Interest Expense $13M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.2M
Income Before Tax -$89M
Income Tax Expense -$89M
Interest And Debt Expense -
Net Income From Continuing Operations -$89M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$99M
Net Income -$89M

Revenue & Profitability

Earnings Performance

STOK Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $272M
Total Current Assets $233M
Cash And Cash Equivalents At Carrying Value $128M
Cash And Short Term Investments $128M
Inventory -
Current Net Receivables $700K
Total Non Current Assets $39M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $30M
Short Term Investments $89M
Other Current Assets $15M
Other Non Current Assets -
Total Liabilities $43M
Total Current Liabilities $40M
Current Accounts Payable $2.5M
Deferred Revenue -
Current Debt -
Short Term Debt $4.6M
Total Non Current Liabilities $2.5M
Capital Lease Obligations $2.3M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.3M
Other Current Liabilities $14M
Other Non Current Liabilities $2.5M
Total Shareholder Equity $229M
Treasury Stock -
Retained Earnings -$491M
Common Stock $5K
Common Stock Shares Outstanding $54M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$87M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.2M
Capital Expenditures $203K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$107M
Cashflow From Financing $131M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$89M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $37M
Total Revenue $37M
Cost Of Revenue $4.4M
Costof Goods And Services Sold $4.4M
Operating Income -$101M
Selling General And Administrative $49M
Research And Development $89M
Operating Expenses $138M
Investment Income Net -
Net Interest Income $13M
Interest Income -
Interest Expense $13M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.2M
Income Before Tax -$89M
Income Tax Expense -$89M
Interest And Debt Expense -
Net Income From Continuing Operations -$89M
Comprehensive Income Net Of Tax -
Ebit -$101M
Ebitda -$99M
Net Income -$89M

STOK News

STOK Profile

Stoke Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Stoke Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing groundbreaking antisense oligonucleotide (ASO) therapies aimed at addressing the root causes of severe genetic disorders. Based in Bedford, Massachusetts, the company leverages its proprietary technology platform to design and optimize ASOs, with a commitment to transforming the lives of patients afflicted by genetic diseases. Stoke's pioneering research and development efforts position it at the forefront of genetic medicine, making it a compelling prospect for institutional investors seeking exposure to the biopharmaceutical sector.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
BIAF
+55.13%
$5.29
RGTI
-2.86%
$31.18
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
DNN
-3.14%
$2.77
PSTV
+9.60%
$0.61
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
BIAF
+55.13%
$5.29
RGTI
-2.86%
$31.18
YAAS
-8.19%
$0.09
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
WOK
-5.22%
$0.08
RIG
+0.79%
$3.18
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
BBD
-2.09%
$3.27
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
LYT
-16.77%
$0.09
AMZN
-0.93%
$218.15
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
RXRX
-5.12%
$4.63
AAPL
-0.54%
$255.46
ATCH
-4.22%
$0.79
SOUN
-2.50%
$15.94
PLTR
-0.86%
$177.57
BITF
-5.22%
$2.54
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
FCX
+1.14%
$35.74
BURU
-10.14%
$0.12
BMNR
+1.69%
$50.41
RMBL
+60.50%
$3.21
ETHD
-5.95%
$3.95
IXHL
-0.01%
$0.59
SHOT
+12.24%
$0.28
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RR
+2.68%
$4.20
CLSK
-5.32%
$13.68
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.36%
$17.76
RAYA
-3.15%
$0.04
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.34%
$4.94
JOBY
+1.63%
$16.12
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.52%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.64%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.39%
$58.38
ABEV
0.00%
$2.29
AQMS
+48.37%
$7.30
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
HBAN
+0.57%
$17.42
ORCL
-2.70%
$283.45
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
AIIO
-15.63%
$2.04
NWTN
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.